Vasalamin
Vessel cytamin — Khavinson-school organ peptide fraction, oral tablet
Vasalamin (Vessel cytamin — Khavinson-school organ peptide fraction, oral tablet) is a longevity & bioregulators research compound. A polypeptide fraction extracted from animal vascular tissue, 155mg per tablet, from the same organ-extract line as the other cytamins. The vascular version of the class claim is that short peptides released from the fraction reach endothelial cells and change which genes those cells transcribe. The school's own vascular work is an epigenetic argument about endothelial cell proliferation in culture, and its own transport papers argue that peptides of this kind need the PEPT and LAT carrier families to cross a membrane at all — carriers built for di- and tripeptides, not for an undefined 155mg fraction.
Vasalamin quick facts
| Route | Oral |
| Frequency | Not established · Not established |
| Half-life | Not characterized — no analytical method for this preparation has been published |
| Forms | Oral |
| Evidence level | No published study of this product. The school's vascular literature is cell-culture work on endothelial proliferation. |
This is the most expensive tablet in the cytamin line and the one with the cheapest possible test attached to it. Blood pressure, ApoB, Lp(a) and hs-CRP are all standardized, all cheap, and all things a vessel product should move if the premise holds. Nobody has reported any of them for it. A PubMed search for the product name on 8 September 2026 returned zero records, so the whole argument for it is an inference from cell-culture work on endothelial cells grown in a dish.
How Vasalamin works
A polypeptide fraction extracted from animal vascular tissue, 155mg per tablet, from the same organ-extract line as the other cytamins. The vascular version of the class claim is that short peptides released from the fraction reach endothelial cells and change which genes those cells transcribe. The school's own vascular work is an epigenetic argument about endothelial cell proliferation in culture, and its own transport papers argue that peptides of this kind need the PEPT and LAT carrier families to cross a membrane at all — carriers built for di- and tripeptides, not for an undefined 155mg fraction.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Vasalamin
Buy Vasalamin at RUPharma →The evidence for Vasalamin
Graded by what exists behind each claim.
✅ Clinically validated
- None. A PubTator3 search of PubMed for this product's name, run 8 September 2026, returned zero records — no trial, no case series, no pharmacokinetic study, no adverse event report.
📊 Correlative data
- The school's vascular work is epigenetic regulation of vascular endothelial cell proliferation during aging (Khavinson 2014), and the broader claim that short peptides stimulate tissue-specific differentiation in aging cells (Khavinson 2012). Both are cell-level arguments about defined molecules.
- The same school's transport papers argue its peptides need the PEPT and LAT carrier families to cross a membrane (Khavinson 2022, 2023). Those carriers move di- and tripeptides.
🧪 Theoretical / extrapolated
- Read the transport argument and the tissue-specificity claim together and they conflict: a two-residue peptide has no tissue of origin. If the active species is small enough to be carried, it is the same molecule whether it came from a vessel, a joint or a steak.
- Blood pressure, ApoB, Lp(a) and hs-CRP are four standardized numbers costing less together than one pack. None has ever been reported for this product.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Vasalamin actually does
The school's own transport model is the most interesting argument against its own tablet, and almost nobody quotes it. Khavinson 2023 assessed the feasibility of moving 26 biologically active ultrashort peptides into cells through the LAT and PEPT carrier families, and Khavinson 2022 makes the same case for POT and LAT transporters. Those carriers exist to move di- and tripeptides and individual amino acids. They are the reason the school's short synthetic peptides are argued to get anywhere at all — and they are the reason an undefined 155 mg tissue fraction has no described route in.
What the vessel claim actually rests on. Khavinson 2014 is an account of epigenetic regulation of vascular endothelial cell proliferation during aging: peptides influencing which genes endothelial cells express as those cells grow old. Khavinson 2012 makes the broader version of the claim, that short peptides stimulate cell differentiation tissue-specifically as cells age. Both are cell-level arguments about defined molecules. Neither used this tablet, and neither reports a vessel measured in a person.
Read the two together and the product has a problem. If the active principle needs PEPT and LAT to reach a cell Khavinson 2023, then the active principle is a peptide of two or three residues — and a two-residue peptide has no tissue of origin. It is the same molecule whether it was cut out of vascular tissue, cartilage or a steak. The product line's entire premise is that the organ the extract came from determines what the extract does, and the school's own transport work points the other way.
What is in the pack. A 155 mg tablet of a nucleoprotein fraction extracted from animal vascular tissue, 40 to a pack, at $53 — the most expensive of the standard cytamins. No composition, no assay, no dissolution data. Ryzhak 2003 describes how the class is manufactured and screened for infectious agents and does not report the contents of any individual product.
Cell, rodent, human — and where it stops
Start with the search. A PubTator3 query of PubMed for vasalamin, run 8 September 2026, returned zero records. No trial, no case series, no pharmacokinetic study, no adverse event report. Everything below is about a different substance and the sentences say which.
The cell rung is the only rung. The vascular literature in this school is endothelial cells in culture Khavinson 2014 and aging cells being pushed toward differentiation Khavinson 2012. Cells in a dish are bathed at a fixed concentration by an experimenter. A vessel in a person is a living tube under pressure, lined by endothelium that is reached through blood after everything the gut does first.
The human rung, and what it is not. Khavinson 2001 is the closest thing to human evidence for this shelf: a 2001 Russian military-medicine paper on cytamines for professional ability and longevity in servicemen. It is about the class, it names no blood pressure, no lipid fraction and no vascular imaging endpoint in its abstract, and it is the only human paper the class search returns from an author who works on it.
The step nobody has taken, stated as a measurement. A vascular product has the cheapest falsification route on this shelf, because the vessel is the one organ whose function is measured in every clinic in the world. Blood pressure, ApoB, Lp(a) and hs-CRP are four standardized numbers, all together cheaper than one pack, and none of them has ever been reported for this product. That is the finding, and it is not the same finding as the product failing.
Vasalamin pharmacokinetics — how much of it actually gets in
What degrades it, and then what would have to carry it. Gastric acid and pepsin start, pancreatic proteases continue, and brush-border peptidases hydrolyze the remainder to amino acids and di- and tripeptides. Whatever survives has to cross the enterocyte, and the school's own answer to how is the PEPT and LAT carrier families Khavinson 2023. Those transporters are saturable, low-affinity, high-capacity for exactly the fragment sizes digestion produces — which is a coherent story for a defined dipeptide and no story at all for an undefined fraction.
The oral barrier, with the number that bounds it. A 155 mg tablet is roughly 3% of the protein in a single egg. Crossing the gut wall is the step nobody has measured, and no oral bioavailability figure has been published for any product in this line. Whatever fraction of it survives as intact peptide enters a circulation already carrying free amino acids at millimolar concentrations from the last meal, and PEPT1 does not distinguish a peptide from a vessel from a peptide from lunch. For an oral extract to have a vascular effect distinguishable from food, something in it has to be both absorbed and unlike food, and neither half has been shown.
The comparator that does not exist here. The brain arm of this family has a measured number from a radiolabeled injection, which at least sets a ceiling. Vascular tissue has no such experiment: no injected vascular extract, no labeled study, no tissue distribution data at all. So the ceiling for this product is not merely unmeasured, it is unmeasured in both directions, and no honest half-life can be stated for a preparation with no published analytical method.
What can be said about timing. Free amino acids and small peptides from a protein load peak within an hour or two and clear over hours. Any pharmacology from this tablet would therefore be a series of brief exposures rather than a steady state, which makes a 40-tablet course a schedule and not an accumulation argument. Vendors who describe these as building up over a course are describing something the pharmacology does not support.
What would have to be true, and how you would know it was not
Four predictions, ordered by what a reader can do this week.
1. Home blood pressure, twice daily, across one pack. Forty tablets is roughly a forty-day course. Two readings a day before and during it gives a paired series with enough measurements to see a 5 mmHg change if one exists. Nobody has published a single blood pressure reading on this product. Prediction: no change beyond normal day-to-day variation, which is itself larger than most people expect.
2. ApoB and Lp(a), baseline and end of course. ApoB counts atherogenic particles and Lp(a) is largely genetic and moves for almost nothing. Prediction: ApoB does not move, and Lp(a) definitely does not — the second one is included precisely because a product that moved it would be extraordinary and worth reporting.
3. hs-CRP is the one with a plausible mechanism and it still will not move. The endothelial argument Khavinson 2014 is about proliferation and gene expression, not about systemic inflammation, so hs-CRP is a weak test of the actual claim. It is named anyway because it is cheap, it is sensitive to real change, and a page that only names markers it expects to be flat is not being falsifiable, it is being safe.
4. Against the product, and it is the school's own argument. If the active principle moves through PEPT and LAT Khavinson 2023, it is two or three residues long, and a two-residue peptide carries no tissue identity. The prediction that follows is that this tablet, the cartilage one and the kidney one would be indistinguishable on any shared endpoint. That experiment has never been run, and a vendor selling seventeen organ names has no reason to run it.
What nobody has tested yet
Nobody has assayed a tablet. Peptide profile and molecular weight distribution by mass spectrometry is a routine analytical run. No vendor publishes one and no independent laboratory has published one for any cytamin. Until that exists, the difference between the vessel tablet and the cartilage tablet is a label.
Nobody has run flow-mediated dilation. It is the standard non-invasive measure of endothelial function, it is exactly the endpoint the school's endothelial work Khavinson 2014 predicts, and it has never been reported for any product in this line. One ultrasound machine, twenty volunteers, and the class's central vascular claim would have its first human test.
Nobody has checked whether the carriers are even engaged. Khavinson 2022 and Khavinson 2023 model the transport of defined ultrashort peptides. Whether anything released from a 155 mg tissue fraction is a substrate for PEPT1 or LAT1 is an in vitro question with a standard method and no published answer.
Extrapolation, labeled as such. If the tissue-of-origin premise is real, an extract of vascular tissue should contain something that an extract of another tissue does not. That is a difference a proteomic comparison of two packs would either find or fail to find in a single week of laboratory time, and it is the cheapest test of the entire product line's premise that anyone could design.
Vasalamin — its own safety story, not its class's
Three things specific to an oral extract of animal vascular tissue.
No adverse event has been published, because no study has. The 8 September 2026 search returned zero records of any kind. An empty safety column here is a statement about how little has been looked at, not a statement that the tablet has been looked at and found harmless.
The sourcing question, and the one document that speaks to it. Ryzhak 2003 reports that the industrial process for this class treats organs from young animals and states that testing by World Health Organization methods indicates the technology excludes infectious agents. That is the manufacturer's school describing its own process, which is worth more than nothing and less than a certificate of analysis. No pack ships with one, and no vendor publishes species, country or animal age.
The readers who buy a vessel product are the readers on anticoagulants. There is no interaction data between this tablet and warfarin, a direct oral anticoagulant, aspirin or a statin. Not reassuring data — no data. A preparation whose contents are unpublished cannot be reasoned about alongside a drug with a narrow therapeutic window, and that combination is a question for a prescriber rather than for a product page.
Sources read for this page
- Khavinson VKh. Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging. Advances in Gerontology 2014 [Russian] · PMID 25051766
- Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules 2023;13(3):552 · PMID 36979488
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
- Khavinson VKh. Peptides tissue-specifically stimulate cell differentiation during their aging. Bulletin of Experimental Biology and Medicine 2012 · PMID 22808515
- Khavinson VKh, Cherniak SI, D'iakonov MM. [Cytamines--preparations for maintaining high professional ability and longevity in servicemen]. Voenno-Meditsinskii Zhurnal 2001 [Russian] · PMID 11338817
- Ryzhak GA, Nekrasov PA, Kiselev OI, Khavinson VKh. Study of protein components of natural peptide regulators. Bulletin of Experimental Biology and Medicine 2003 · PMID 12717513
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
Vasalamin — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Vasalamin — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Vasalamin moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Vasalamin in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Vasalamin
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Vasalamin — frequently asked questions
What is Vasalamin?
Vasalamin (Vessel cytamin — Khavinson-school organ peptide fraction, oral tablet) is a longevity & bioregulators research compound. A polypeptide fraction extracted from animal vascular tissue, 155mg per tablet, from the same organ-extract line as the other cytamins. The vascular version of the class claim is that short peptides released from the fraction reach endothelial cells and change which genes those cells transcribe. The school's own vascular work is an epigenetic argument about endothelial cell proliferation in culture, and its own transport papers argue that peptides of this kind need the PEPT and LAT carrier families to cross a membrane at all — carriers built for di- and tripeptides, not for an undefined 155mg fraction.
Where can I find Vasalamin dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full Vasalamin protocol are available to members inside Skool. This public page covers what Vasalamin is, how it works and the evidence.
What is the half-life of Vasalamin?
Vasalamin has an approximate half-life of Not characterized — no analytical method for this preparation has been published, which is part of what determines how often it's dosed.
What's the evidence behind Vasalamin?
Current evidence level: No published study of this product. The school's vascular literature is cell-culture work on endothelial proliferation.. Vasalamin is offered for research purposes only and is not an approved medicine.
What Vasalamin is used for
Vasalamin appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.